Aquaculture Vaccines Market: By Vaccine Type (Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine, and Others), By Application (Bacterial Infection, Viral Infections, Combined Bacterial and Viral Infections, and Others), By Route of Administration (Immersion Vaccines, Injection Vaccines, and Oral Vaccines), By Species (Salmon, Seabass and Seabream, Tilapia, Trout, Turbot, and Carp), and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

Aquaculture Vaccine Market is valued at USD 482.6 million in 2022 and is projected to reach 817.8 million by 2029, at a CAGR of 7.9% from 2023-29. Due to surge in the of prevalence of bacterial and viral infections among aquaculture species, increase in aquaculture production around the globe, and rise in adoption of vaccines by aquaculture farmers. Development and launch of innovative vaccines to treat various infectious diseases in aquaculture species boosting the revenue growth of the market. For instance, In March 2018, Hipra launched Icthiovac VR/PD injectable vaccine for seabass against Vibriosis and Pasteurellosis in Greece. Apart from the aforementioned dynamics, Raise in funding for the research and development of innovative aquaculture vaccines boost the market over forecast years. For instance, In March 2015, The Scottish Aquaculture Innovation Center (SAIC) has announced it is issuing grants worth almost GBP 950,000 to two major salmon farming research projects proposed by leading farmed salmon companies on sea lice and salmon vaccinations.   

Aquaculture Vaccine Market Key Development:

• In April 2021, CIBA launched Nodavac-R, an injectable recombinant viral nervous necrosis (VNN) vaccine that can effectively prevent VNN caused by RGNNV in fingerlings and prevent vertical transmission in brooders. All fish species, including milkfish, grey mullet, and mangrove red snapper susceptible to VNN, can use the Nodavac-R. CIBA is also developing an oral vaccine that can administer through feed and immersion.
• In November 2019, MSD Animal Health launched the AQUAVAC® Strep Sa-Si injectable and dip immersion vaccine against Streptococcis in tilapia fish in Latin America.